An enhanced bunionectomy model as a potential tool for early decision-making in the development of new analgesics
Hao Wang(Johnson & Johnson (United States)), Alise Reicin(Merck & Co., Inc., Rahway, NJ, USA (United States)), Chan Beals(Merck & Co., Inc., Rahway, NJ, USA (United States)), Suzanne Lukac(Merck & Co., Inc., Rahway, NJ, USA (United States)), Robert A. Medve(Rocky Mountain Multiple Sclerosis Clinic), Patricia A. Smiley(Merck & Co., Inc., Rahway, NJ, USA (United States)), Alice Jackson, Gary Herman(Regeneron (United States)), Cynthia Gargano(Merck & Co., Inc., Rahway, NJ, USA (United States)), Melissa Drexel(Merck & Co., Inc., Rahway, NJ, USA (United States)), Lynn R. Webster(Adherent Technologies (United States)), Marcella Ruddy(Regeneron (United States)), Amy O. Johnson‐Levonas(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 26
Related Papers
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
|New England Journal of Medicine|2020|1.8k
Predicting Aberrant Behaviors in Opioid-Treated Patients: Preliminary Validation of the Opioid Risk Tool
|Pain Medicine|2005|1.1k
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis
|JAMA Dermatology|2019|516
Risk Factors for Opioid-Use Disorder and Overdose
|Anesthesia & Analgesia|2017|504
Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis
|New England Journal of Medicine|2022|452